Regeneron Pharmaceuticals (REGN) closed at $955.47 on November 13, 2026, up 0.4% from the previous close, on volume of 629,621 shares (30-day average 832,773).
Data as of November 13, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 29, 2026 | Seagull With Call Spread | 06-Nov-26750 P : 835 C : 880 C | 1,050 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
SA Asks: What are the most attractive Big Pharma stocks right now?
Seeking Alpha News (Sun, 15-Nov 2:56 PM ET)
The Week That Was, The Week Ahead: Macro and Markets, November 15
TipRanks (Sun, 15-Nov 4:14 AM ET)
Globe Newswire (Thu, 12-Nov 5:00 PM ET)
Regeneron Updates Obesity Drug Study as Investors Await Results
TipRanks (Thu, 12-Nov 11:30 AM ET)
Regeneron Buy Rating Maintained on Promising MASH Pipeline and Unchanged $1,175 Price Target
TipRanks (Wed, 11-Nov 11:15 AM ET)
Citi Sticks to Its Hold Rating for Regeneron (REGN)
TipRanks (Wed, 11-Nov 7:26 AM ET)
Regeneron’s MASH Pipeline Supports Buy Rating; Price Target Unchanged at $1,030
TipRanks (Wed, 11-Nov 6:16 AM ET)
Globe Newswire (Sun, 8-Nov 4:00 PM ET)
Regeneron Announces Investor Conference Presentations
Globe Newswire (Mon, 2-Nov 4:05 PM ET)
Regeneron soars as Q3 2026 non-GAAP EPS jumps 70% and Sanofi collaboration revenue climbs 68%
Market Chameleon (Fri, 30-Oct 6:28 AM ET)
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Regeneron Pharmaceuticals trades on the NASDAQ stock market under the symbol REGN.
As of November 16, 2026, REGN stock price climbed to $959.87 with 242,125 million shares trading.
REGN has a beta of -0.03, meaning it tends to be less sensitive to market movements. REGN has a correlation of 0.00 to the broad based SPY ETF.
REGN has a market cap of $99.30 billion. This is considered a Large Cap stock.
Last quarter Regeneron Pharmaceuticals reported $5 billion in Revenue and $20.07 earnings per share. This beat revenue expectation by $556 million and exceeded earnings estimates by $4.32.
In the last 3 years, REGN traded as high as $1,211.20 and as low as $476.49.
The top ETF exchange traded funds that REGN belongs to (by Net Assets): VTI, QQQ, VOO, IVV, SPY.
REGN has outperformed the market in the last year with a price return of +38.6% while the SPY ETF gained +11.6%. REGN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +19.2% and +3.4%, respectively, while the SPY returned -4.3% and -1.8%, respectively.
REGN support price is $932.77 and resistance is $978.17 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that REGN shares will trade within this expected range on the day.